Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Birgitta Johansson in
Google Scholar
PubMed
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Search for other papers by Mats Holmberg in
Google Scholar
PubMed
Department of Pedagogical, Curricular and Professional Studies, Faculty of Education, University of Gothenburg, Gothenburg, Sweden
Search for other papers by Simon Skau in
Google Scholar
PubMed
Search for other papers by Helge Malmgren in
Google Scholar
PubMed
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
Introduction Untreated hyperthyroid patients with Graves’ disease (GD, autoimmune hyperthyroidism) often report fatigue, cognitive problems, and emotional distress. Once the patients are regarded as clinically recovered and euthyroid, the
Search for other papers by Sébastien Verdickt in
Google Scholar
PubMed
Search for other papers by Falco Van Nes in
Google Scholar
PubMed
Search for other papers by Carolien Moyson in
Google Scholar
PubMed
Search for other papers by Toon Maes in
Google Scholar
PubMed
Search for other papers by Paul Van Crombrugge in
Google Scholar
PubMed
Search for other papers by Annick Van den Bruel in
Google Scholar
PubMed
Search for other papers by Brigitte Decallonne in
Google Scholar
PubMed
Introduction Radioactive iodine (RAI) has been used for the treatment of patients with Graves’ hyperthyroidism since the 1950s. After a single RAI administration, patients ideally become euthyroid but frequently develop hypothyroidism. On the
London School of Hygiene and Tropical Medicine, London
Search for other papers by Peter N. Taylor in
Google Scholar
PubMed
Search for other papers by Bijay Vaidya in
Google Scholar
PubMed
Introduction Hyperthyroidism in pregnancy is a serious condition, resulting in increased risk of adverse obstetric outcomes including miscarriage, stillbirth, pre-term birth and intra-uterine growth restriction [ 1 ]. Its management is complex
Institute of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Search for other papers by Mats Holmberg in
Google Scholar
PubMed
Search for other papers by Helge Malmgren in
Google Scholar
PubMed
Search for other papers by Peter F Berglund in
Google Scholar
PubMed
Search for other papers by Birgitta Johansson in
Google Scholar
PubMed
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Department of Endocrinology, Sahlgrenska University Hospital, Göteborg, Sweden
Gothenburg Centre for Person Centred-Care (GPCC), Göteborg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
Introduction Mental symptoms and reduced quality of life (QoL) are common brain-derived problems in untreated Graves’ hyperthyroidism ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ). In a 2006 review (meta
Search for other papers by Christiaan F Mooij in
Google Scholar
PubMed
Department of Pediatric Endocrinology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
Search for other papers by Timothy D Cheetham in
Google Scholar
PubMed
Search for other papers by Frederik A Verburg in
Google Scholar
PubMed
Search for other papers by Anja Eckstein in
Google Scholar
PubMed
Endocrine Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
Search for other papers by Simon H Pearce in
Google Scholar
PubMed
Search for other papers by Juliane Léger in
Google Scholar
PubMed
Search for other papers by A S Paul van Trotsenburg in
Google Scholar
PubMed
Introduction Purpose and scope of guideline Hyperthyroidism caused by Graves’ disease (GD) is a relatively rare disease in children. Although treatment options are the same as in adults – antithyroid drugs (ATD), radioactive iodine (RAI
Search for other papers by P. Beck-Peccoz in
Google Scholar
PubMed
Search for other papers by A. Lania in
Google Scholar
PubMed
Search for other papers by A. Beckers in
Google Scholar
PubMed
Search for other papers by K. Chatterjee in
Google Scholar
PubMed
Search for other papers by J.-L. Wemeau in
Google Scholar
PubMed
Introduction The syndrome of ‘inappropriate secretion of TSH' was the term coined originally [ 1 ] to indicate two forms of central hyperthyroidism, i.e. thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) and resistance to thyroid
Search for other papers by Hsu-Hua Tseng in
Google Scholar
PubMed
Search for other papers by Yen-Bo Lin in
Google Scholar
PubMed
Search for other papers by Kuan-Yu Lin in
Google Scholar
PubMed
Search for other papers by Chia-Hung Lin in
Google Scholar
PubMed
Search for other papers by Hung-Yuan Li in
Google Scholar
PubMed
Search for other papers by Chia-Hsuin Chang in
Google Scholar
PubMed
Search for other papers by Yi-Ching Tung in
Google Scholar
PubMed
Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei, Taiwan
Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan
Search for other papers by Pei-Lung Chen in
Google Scholar
PubMed
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
Search for other papers by Chih-Yuan Wang in
Google Scholar
PubMed
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
Search for other papers by Wei-Shiung Yang in
Google Scholar
PubMed
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
Center of Anti-Aging and Health Consultation, National Taiwan University Hospital, Taipei, Taiwan
Search for other papers by Shyang-Rong Shih in
Google Scholar
PubMed
( 22 ). Those with type 2 DM, gestational DM, or other types of DM were excluded. Overt hyperthyroidism is defined as elevated serum concentrations of thyroid hormones with suppressed serum thyroid-stimulating hormone (TSH) levels. Subclinical
Search for other papers by Beatrice Engelmann in
Google Scholar
PubMed
Search for other papers by Julia Bischof in
Google Scholar
PubMed
Search for other papers by Anne-Luise Dirk in
Google Scholar
PubMed
Search for other papers by Nele Friedrich in
Google Scholar
PubMed
Search for other papers by Elke Hammer in
Google Scholar
PubMed
Search for other papers by Thomas Thiele in
Google Scholar
PubMed
Search for other papers by Dagmar Führer in
Google Scholar
PubMed
Search for other papers by Georg Homuth in
Google Scholar
PubMed
Search for other papers by Georg Brabant in
Google Scholar
PubMed
Search for other papers by Uwe Völker in
Google Scholar
PubMed
Introduction Since the first report more than a century ago, a relation between hyperthyroidism and hypercoagulation has been suspected [ 1 ]. This has been further substantiated in a number of recent studies where patients with various causes
Department of Oto-Rhino-Laryngology – Head and Neck Surgery, University Hospital Essen, Essen, Germany
Search for other papers by Anke Schlüter in
Google Scholar
PubMed
Department of Ophthalmology, University Hospital Essen, Essen, Germany
Search for other papers by Anja K. Eckstein in
Google Scholar
PubMed
Search for other papers by Alexandra Brenzel in
Google Scholar
PubMed
Search for other papers by Mareike Horstmann in
Google Scholar
PubMed
Search for other papers by Stephan Lang in
Google Scholar
PubMed
Search for other papers by Utta Berchner-Pfannschmidt in
Google Scholar
PubMed
Search for other papers by J. Paul Banga in
Google Scholar
PubMed
Search for other papers by Salvador Diaz-Cano in
Google Scholar
PubMed
Introduction Graves disease (GD) is caused by autoantibodies that induce hyperthyroidism by mimicking the action of TSH and activating the TSH receptor (TSHR). The defining component of hyperthyroidism is thyroid follicular hyperplasia
Search for other papers by Nandhini Lakshmana Perumal in
Google Scholar
PubMed
Search for other papers by Jayakumar Selvi in
Google Scholar
PubMed
Search for other papers by Kalyani Sridharan in
Google Scholar
PubMed
Search for other papers by Jayaprakash Sahoo in
Google Scholar
PubMed
Search for other papers by Sadishkumar Kamalanathan in
Google Scholar
PubMed
abnormal glucose tolerance and diabetes mellitus have been reported to occur in a significant proportion of patients with hyperthyroidism [ 2 ]. Several factors like changes in insulin resistance, beta-cell function, abnormal gastric emptying, and